NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Phase 1

Active, not recruiting

Conditions: Clear Cell Renal Cell Carcinoma
Renal Cell Carcinoma
Sarcomatoid Renal Cell Carcinoma
Stage III Bladder Cancer AJCC v8
Stage III Urethral Cancer AJCC v8
Bladder Urothelial Carcinoma
Invasive Bladder Plasmacytoid Urothelial Carcinoma
Invasive Bladder Sarcomatoid Urothelial Carcinoma
Stage III Renal Pelvis Cancer AJCC v8
Stage IV Penile Cancer AJCC v8

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Drug: Cabozantinib S-malate
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Imaging
Biological: Ipilimumab
Biological: Nivolumab

First Posted Date: 2015-07-14

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 152

Registration Number: NCT02496208

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 5 locations

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Phase 1

Active, not recruiting

Conditions: Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Metastatic Lung Non-Small Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Elastography
Procedure: Multigated Acquisition Scan
Biological: Necitumumab
Drug: Osimertinib

First Posted Date: 2015-07-14

Last Posted Date: 2025-06-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 138

Registration Number: NCT02496663

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 12 locations

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

Phase 1

Terminated

Conditions: Renal Cell Carcinoma
Hereditary Leiomyomatosis
Renal Cell Cancer

Interventions: Drug: Vandetanib
Drug: Vandetanib/Metformin
Drug: Metformin

First Posted Date: 2015-07-13

Last Posted Date: 2021-01-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 7

Registration Number: NCT02495103

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma

Phase 1

Withdrawn

Conditions: Metastatic Melanoma

Interventions: Biological: AKTi-treated TIL
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Aldesleukin

First Posted Date: 2015-07-03

Last Posted Date: 2017-07-27

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT02489266

Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma

Phase 2

Completed

Conditions: Recurrent Osteosarcoma

Interventions: Drug: Glembatumumab Vedotin
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2015-07-02

Last Posted Date: 2022-01-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT02487979

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States

and more 152 locations

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

Phase 1

Completed

Conditions: Carcinoma, Non-Small -Cell Lung
Small Cell Lung Carcinoma
Uterine Cervical Neoplasms
Ovarian Neoplasms
Carcinoma, Neuroendocrine
Extrapulmonary Small Cell Cancer

Interventions: Drug: Topotecan
Drug: VX-970 (M6620)

First Posted Date: 2015-07-01

Last Posted Date: 2025-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 62

Registration Number: NCT02487095

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
B Acute Lymphoblastic Leukemia
Refractory Adult Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Recurrent Adult Acute Lymphoblastic Leukemia
T Acute Lymphoblastic Leukemia

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Sapanisertib

First Posted Date: 2015-06-29

Last Posted Date: 2025-03-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT02484430

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 11 locations

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

Phase 2

Completed

Conditions: Metastatic Osteosarcoma
Recurrent Osteosarcoma
Metastatic Malignant Neoplasm in the Lung

Interventions: Biological: Dinutuximab
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Biological: Sargramostim

First Posted Date: 2015-06-29

Last Posted Date: 2023-10-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT02484443

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Eastern Maine Medical Center, Bangor, Maine, United States
🇺🇸
New York Medical College, Valhalla, New York, United States

and more 127 locations

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Phase 1

Active, not recruiting

Conditions: Colorectal Neoplasms
Breast Neoplasms

Interventions: Drug: Olaparib
Drug: Cediranib
Drug: Durvalumab

First Posted Date: 2015-06-29

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 268

Registration Number: NCT02484404

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

Phase 1

Terminated

Conditions: Metastatic Breast Carcinoma
Stage IIIB Breast Cancer AJCC v7
Advanced Breast Carcinoma
Stage III Breast Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7
Triple-Negative Breast Carcinoma
Stage IIIA Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Onalespib
Drug: Paclitaxel
Other: Pharmacological Study

First Posted Date: 2015-06-17

Last Posted Date: 2022-11-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT02474173

Locations: 🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy